Ajanta Pharma Limited — Important, 28-10-2024: Financial Result Updates

Ajanta Pharma reported a strong Q2 FY 2025, with consolidated earnings showing a 15% increase in revenue, reaching ₹1,187 crore. The board approved the first interim dividend of ₹28 per share, totaling ₹350 crore. Highlights include an 11% rise in profit after tax to ₹216 crore and a healthy EBITDA margin of 26%. Notable growth was driven by branded generics in India, Asia, and Africa, with the US generic segment maintaining stability despite price pressures.